Functionally validated monoclonal hybridoma leads in six weeks.

BinderGen™ combines proprietary target sensitization with SMARTFusion™ to capture robust immune diversity as confirmed monoclonal hybridomas. Designed to compress discovery timelines without compromising monoclonality, immune diversity, or biologic rigor, the output is built to carry real program decisions.

BinderGen™Built for biologic rigor

A hybridoma discovery platform engineered to compress biologic timelines without sacrificing immune diversity, monoclonality, or the mouse biology teams already trust.

Enter the engineAnti-ID / ADAIND-ready anti-ID

Anti-idiotype and anti-drug antibody programs for biologics teams that need dependable reagents, assay support, and development readiness on compressed timelines.

Open the laneResearch servicesScientific infrastructure

BLI characterization, assay development, immunization-only programs, AI-ready immune datasets, and plasma cell workflows supporting discovery and development execution.

View capabilitiesFull storyThe platform arc

Follow the system from immune sensitization through SMARTFusion™, monoclonal hybridoma generation, functional validation, and downstream development readiness.

Begin the story
In vivo · Hybridoma · Affinity-ranked

BinderGen™

Why choose the hybridoma approach?

Robust sensitization in the BinderGen hybridoma antibody discovery workflow
01
01 · StatementRobust sensitization

01 Discovery begins inside the immune system, where target exposure creates a biologically informed starting point instead of a purely synthetic approximation.

Why speed matters

Timeline delays create downstream pressure.

Slow discovery does more than delay the start. It delays monoclonal confirmation, postpones decisive functional experiments, and stretches the distance between early binder signal and a program worth advancing.

BinderGen™ is designed around a simple strategic belief: when teams evaluate confirmed monoclonal hybridoma-derived leads earlier, they can make downstream decisions from evidence rather than provisional binder data.

Confirmation

Early binder signal is not the same as confirmed monoclonal hybridoma output. Timeline delays postpone the point where teams know what they actually have.

Iteration

Every delayed monoclonal panel delays functional testing, candidate comparison, specificity work, and the next go or no-go decision.

Translation

The earlier the antibody signal is confirmed, the earlier teams can plan PK, ADA, assay, reagent, and development-enabling work.

BinderGen™

Designed to preserve immune diversity during accelerated monoclonal hybridoma generation.

BinderGen™ combines proprietary target sensitization with SMARTFusion™ workflows to preserve immune diversity through limiting-dilution monoclonal hybridoma capture, improving hit retention while reducing attrition from discovery through confirmation. The system is designed to procure rare binders without subcloning while maintaining native biologic context, native heavy/light chain pairing, and decision-quality repertoire breadth. Validated across transgenic, knockout, and humanized mouse models, BinderGen™ can also operate inside client-owned, private, or licensed mouse strains.

Speed only matters when the output is monoclonal, functional, confirmed, and compatible with the biology a client already trusts.

Target to antibody panel

>70% timeline reduction
Week 0
Week 0Program ignition
Week 6

Week 0

Antigen design

Programs begin with antigen strategy and target-directed immune pressure designed to create biologic signal, downstream assay compatibility, and a discovery path worth building around.

Week 0

Antigen design

Programs begin with antigen strategy and target-directed immune pressure designed to create biologic signal, downstream assay compatibility, and a discovery path worth building around.
Client-strain compatibleHumanized-compatibleTransgenic validatedKnockout-readyMonoclonality confirmedIn vivo matured

Platform architecture

A discovery system built for what comes next.

Immunovive’s platform is not a single isolated screen. It is a coordinated antibody infrastructure layer built to keep discovery quality, model flexibility, assay readiness, and program continuity connected. If a client already owns or licenses the mouse model, BinderGen™ can be positioned around that biology rather than replacing it.

The point is not only to identify binders faster. It is to deliver monoclonal hybridoma-derived leads with functional evidence, native pairing, repertoire diversity, affinity context, and enough confidence to carry the next set of decisions.

Discovery integrity

Programs move better when the output reflects real biologic signal, monoclonal confirmation, native heavy/light pairing, and enough repertoire diversity to support deliberate choice.

Model flexibility

BinderGen™ has been validated across transgenic, knockout, and humanized mouse systems, including customer-owned or licensed strains that need to remain inside the discovery plan.

Program continuity

Immunovive keeps discovery connected to downstream assay compatibility, reagent planning, and development decisions instead of treating antibody generation as an isolated screen.

Anti-idiotype and anti-drug antibodies

Anti-ID programs for biologics teams under real development pressure.

For biologics teams moving toward IND-enabling work, anti-idiotype and anti-drug antibodies become the reagents behind PK assays, ADA assays, exposure measurement, PK bridging, reagent fit-for-purpose screening, and assay confidence. Immunovive brings hybridoma speed, monoclonal reliability, and assay-development depth to a practical bottleneck that often appears when timelines are already tight, without forcing an oversized therapeutic-discovery campaign.

Every biologics program eventually needs trusted reagents to measure the therapeutic it created.

DiscoverTherapeutic antibody
PrepareAnti-idiotype reagent
AdvancePK · ADA · IND assays

Built for compressed timelines

Anti-idiotype and anti-drug antibody needs often surface when PK, ADA, exposure, and assay work are already under pressure.

Reliable monoclonal reagents

Many anti-ID programs need dependable hybridoma-derived reagents quickly, not an oversized therapeutic discovery campaign.

Assay experience included

Immunovive pairs anti-ID generation with practical assay-development fluency, including PK bridging, ADA assay support, exposure measurement, and reagent fit-for-purpose screening.

What becomes possible

When discovery arrives with functional evidence, diversity, affinity context, and downstream readiness, teams gain more than time. They gain strategic room to compare candidates, understand tradeoffs, and choose the path a program can actually support.

More room to choose the right biologics path.

Candidate comparison earlier

Teams can compare function, specificity, affinity context, and assay fit before a single narrow answer defines the lead path.
FunctionSpecificityAssay fit

Better tradeoff decisions

A diverse monoclonal panel gives programs room to balance potency, binding behavior, epitope profile, and downstream practicality.
Affinity rankingEpitope contextLead choice

Cleaner path selection

Discovery output stays connected to the reagent, assay, and development questions that determine whether a candidate can keep moving.
Native pairingDevelopment readinessProgram continuity
Where the system matters

Therapeutic antibody discovery

For teams that need functionally validated monoclonal hybridoma leads with speed, diversity, and biological fidelity.

Client-owned mouse programs

Bring your own mouse model: compatible with client-owned, private, licensed, transgenic, knockout, and humanized systems.

Anti-idiotype generation

For biologics teams that need dependable anti-drug antibody reagents before PK, ADA, and IND timelines compress.

AI-ready immune datasets

Immunization-only programs and plasma-cell workflows can support off-site discovery and machine-learning-enabled antibody campaigns.

Platform services

Scientific infrastructure around the BinderGen™ engine.

Not every customer needs the full BinderGen™ program on day one. Immunovive also supports the infrastructure around antibody discovery as standalone support or as part of a broader BinderGen™ program: BLI kinetic ranking, assay development for anti-ID/ADA/PK workflows, immunization-only work in client-owned mouse systems, AI-ready immune datasets, and plasma cell preparation for downstream discovery.

BLI characterization

Kinetic ranking, affinity context, and interaction profiling for teams comparing binding behavior across candidate panels, available independently or inside a broader BinderGen™ program.

Assay development

Custom readouts for anti-ID, ADA, PK bridging, exposure measurement, reagent fit-for-purpose screening, and translational workflows where the assay must match the biology.

Vivarium programs

Immunization-only support for teams bringing client-owned, private, licensed, transgenic, knockout, or humanized mouse systems.

Immune datasets

AI-ready immunized-mouse datasets and plasma cell preparation for off-site downstream discovery workflows.

About Immunovive

Better discovery changes everything that follows.

Immunovive was built around a disciplined belief: discovery should create confirmed monoclonal output, not just an early binder.

BinderGen™ accelerates the front end while anti-idiotype, assay, and characterization capabilities preserve readiness for the work that follows.

Devin Turner, founder of Immunovive and antibody discovery entrepreneur

Founder-led scientific execution

Shaped by antibody discovery experience under real translational pressure.

Prior to Immunovive, Devin Turner founded Abveris, an antibody discovery company later acquired by Twist Bioscience. That history informs the company’s operating standard: move quickly, but keep the biology, ownership, and downstream path intact from the beginning.

Abveris founder
Twist Bioscience acquisition
Antibody discovery innovator

Scientific signals

A window into how Immunovive thinks.

Not every program needs the same intervention. Some need functionally validated monoclonal leads earlier. Others need assay readiness, anti-idiotype planning, or a cleaner transition into development execution.

Immunovive looks for the scientific pressure points that appear before they become operational bottlenecks.

Monoclonal proof

The value of speed is not only the weeks saved. It is reaching confirmed monoclonal output early enough to act on it.

Readiness pressure

Reagent, PK, ADA, and assay needs often become visible late. Stronger programs plan for them before the timeline tightens.

Program continuity

The handoff from discovery to development is where native pairing, assay fit, and candidate choice are either preserved or quietly lost.

External signal

The phrases antibody teams remember.

Therapeutic discovery

“best-behaving molecules I have ever seen”

Came out of BinderGen™ while other providers were still immunizing.

VP, leading European VC

Immunization performance

“Exceptional serum titers in the BinderGen™ immunization timeframe gave us a better shot at difficult antigen goals.”

VP of Research, large US biotech

Start a conversation

Bring the target. Build the path.

Start with the target, timeline, and downstream decisions that matter. Immunovive can help clarify whether BinderGen™, anti-idiotype generation, or both belong in the program plan.

Inquiries are sent directly to CEO and Founder, Devin Turner for confidential review.